Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease.
Saved in:
| Title: | Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease. |
|---|---|
| Authors: | Landau, Heather1 (AUTHOR) Landauh@mskcc.org, Pandit-Taskar, Neeta1 (AUTHOR), Hassoun, Hani1 (AUTHOR), Cohen, Adam2 (AUTHOR), Lesokhin, Alex1 (AUTHOR), Lendvai, Nikoletta1 (AUTHOR), Drullinsky, Pamela1 (AUTHOR), Schulman, Philip1 (AUTHOR), Jhanwar, Suresh1 (AUTHOR), Hoover, Elizabeth1 (AUTHOR), Bello, Christina1 (AUTHOR), Riedel, Elyn1 (AUTHOR), Nimer, Stephen D.1 (AUTHOR), Comenzo, Raymond L.3 (AUTHOR) |
| Source: | Leukemia & Lymphoma. Feb2012, Vol. 53 Issue 2, p275-281. 7p. 3 Charts, 2 Graphs. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 10428194 |
|---|---|
| DOI: | 10.3109/10428194.2011.606943 |
